Tofogliflozin (Type 2 Diabetes)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26
6 Opportunity and Unmet Need 28
6.1 Overview 28
6.2 Unmet Needs 29
6.2.1 Drugs Providing Sustained Glycemic Control 29
6.2.2 Drugs with Non-Glycemic Benefits 30
6.2.3 Increased Patient Compliance 31
6.2.4 Drugs with Improved Side-Effect Profiles 32
6.2.5 Earlier Diagnosis 33
6.3 Unmet Needs Gap Analysis 34
6.4 Oral Therapy with Sustainable Efficacy 35
6.5 Oral Therapy Offering Weight Loss 35
6.6 Cardio-metabolic Therapy 36
6.7 Promotion of Type 2 Diabetes Drugs in Emerging Markets 36
7 Pipeline Assessment 37
7.1 Overview 37
7.2 Promising Drugs in Clinical Development 38
8 Tofogliflozin 43
8.1 Overview 43
8.2 Efficacy 44
8.3 Safety 45
8.4 Dosing and Formulation 45
8.5 Potential Clinical Positioning 45
8.6 Potential Commercial Positioning 45
8.7 Pricing and Reimbursement 45
8.8 SWOT Analysis 46
8.9 Forecast 47
9 Appendix 48
9.1 Bibliography 48
9.2 Abbreviations 50
9.3 Methodology 51
9.4 Forecasting Methodology 51
9.4.1 Diagnosed Type 2 Patients 51
9.4.2 Percent Drug-Treated Patients 52
9.4.3 Drugs Included in Each Therapeutic Class 52
9.4.4 General Pricing Assumptions 53
9.4.5 Pricing of Pipeline Agents 53
9.5 Physicians and Specialists Included in this Study 54
9.6 About the Authors 56
9.6.1 Analyst II – CVMD 56
9.6.2 Therapy Director – CVMD and Infectious Disease 56
9.6.3 Global Head of Healthcare 57
9.7 About GlobalData 58
9.8 Disclaimer 58